Biblio

Found 359 results
[ Author(Asc)] Keyword Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
G. H. Windbichler, Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Muller-Holzner, E., and Marth, C., Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial, Br J Cancer, vol. 82, pp. 1138-44, 2000.
P. Wimberger, Lehmann, N., Kimmig, R., Burges, A., Meier, W., Hoppenau, B., du Bois, A., and -OVAR, A. G. O., Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR), Gynecol Oncol, vol. 100, pp. 300-7, 2006.
C. W. Whitney, Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, Jr., W. C., Clarke-Pearson, D. L., and Liao, S. Y., Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study, J Clin Oncol, vol. 17, pp. 1339-48, 1999.
K. Wheatley and Gray, R., ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit, Lancet, vol. 362, p. 1333; author reply 1334, 2003.
S. A. Welch, Hirte, H., Elit, L., Schilder, R. J., Wang, L., Macalpine, K., Wright, J. J., and Oza, A. M., Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium, Int J Gynecol Cancer, vol. 20, pp. 787-93, 2010.
B. Weber, Largillier, R., Ray-Coquard, I., Yazbek, G., Meunier, J., Alexandre, J., Dauba, J., Spaeth, D., Delva, R., Joly, F., Pujade-Lauraine, E., Copel, L., and France, G. I. N. E. C. O. Group, A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial, Support Care Cancer, vol. 21, pp. 1947-54, 2013.
Y. Watanabe, Aoki, D., Kitagawa, R., Takeuchi, S., Sagae, S., Sakuragi, N., Yaegashi, N., and Group, D. Committee, Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey, Gynecol Oncol, vol. 105, pp. 325-8, 2007.
Y. Watanabe, Kitagawa, R., Aoki, D., Takeuchi, S., Sagae, S., Sakuragi, N., Yaegashi, N., and Group, D. Committee, Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group, Gynecol Oncol, vol. 115, pp. 456-9, 2009.
U. Wagner, Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I. B., Piccirillo, M. C., Fossati, R., Gebski, V., and Lauraine, E. P., Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients., Br J Cancer, vol. 107, no. 4, p. 591, 2012.
H. C. Wagenaar, Pecorelli, S., Vergote, I. B., Curran, D., Wagener, D. J., Kobierska, A., Bolis, G., Bokkel-Huinink, W. T., Lacave, A. J., Madronal, C., Forn, M., de Oliveira, C. F., Mangioni, C., Nooij, M. A., Goupil, A., Kerbrat, P., Marth, C. H., Tumolo, S., Herben, M. G., Zanaboni, F., and Vermorken, J. B., Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer, Eur J Gynaecol Oncol, vol. 22, pp. 187-93, 2001.
H. C. Wagenaar, Pecorelli, S., Vergote, I. B., Curran, D., Wagener, D. J., Kobierska, A., Bolis, G., Bokkel-Huinink, W. T., Lacave, A. J., Madronal, C., Forn, M., de Oliveira, C. F., Mangioni, C., Nooij, M. A., Goupil, A., Kerbrat, P., Marth, C. H., Tumolo, S., Herben, M. G., Zanaboni, F., and Vermorken, J. B., Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer., Eur J Gynaecol Oncol, vol. 22, no. 3, pp. 187-93, 2001.
V
A. Viswanathan, Creutzberg, C. L., Craighead, P., McCormack, M., Toita, T., Narayan, K., Reed, N. Simon, Long, H. J., Kim, H. - J., Marth, C., Lindegaard, J. C., Cerrotta, A., Small, W., and Trimble, E. L., International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG)., Int J Radiat Oncol Biol Phys, vol. 82, no. 1, pp. 250-5, 2012.
J. B. Vermorken, The role of intraperitoneal chemotherapy in epithelial ovarian cancer., Int J Gynecol Cancer, vol. 10, no. S1, pp. 26-32, 2000.
J. B. Vermorken and Hoekman, K., Chemotherapy for gynecologic malignancies., Curr Opin Oncol, vol. 7, no. 5, pp. 457-65, 1995.
J. B. Vermorken, Harper, P. G., and Buyse, M., The role of anthracyclines in epithelial ovarian cancer., Ann Oncol, vol. 10 Suppl 1, pp. 43-50, 1999.
J. B. Vermorken, Huinink, W. W. ten Bok, Eisenhauer, E., Favalli, G., Belpomme, D., Conte, P. F., and Kaye, S. B., Advanced ovarian cancer. Carboplatin versus cisplatin., Ann Oncol, vol. 4 Suppl 4, pp. 41-8, 1993.
J. B. Vermorken, Consolidation therapy in patients with advanced ovarian cancer., Eur J Gynaecol Oncol, vol. 15, no. 1, pp. 7-13, 1994.
J. B. Vermorken, Parmar, M. K. B., Brady, M. F., Eisenhauer, E., Högberg, T., Ozols, R. F., Rochon, J., Rustin, G. J. S., Sagae, S., Verheijen, R. H. M., InterGroup, G. Cancer, ,, /NCRI, M. R. C., ,, -CTG, N. C. I. C., ,, -OVAR, A. G. O., and , Clinical trials in ovarian carcinoma: study methodology, Ann Oncol, vol. 16 Suppl 8, pp. viii20-viii29, 2005.
J. B. Vermorken, Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG)., Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 73-6, 2001.
J. B. Vermorken and Pecorelli, S., Clinical trials in patients with epithelial ovarian cancer: past, present and future., Eur J Surg Oncol, vol. 22, no. 5, pp. 455-66, 1996.
J. B. Vermorken, Åvall-Lundqvist, E., Pfisterer, J., and Bacon, M., The Gynecologic Cancer Intergroup (GCIG): history and current status., Ann Oncol, vol. 16 Suppl 8, pp. viii39-viii42, 2005.
J. B. Vermorken, Åvall-Lundqvist, E., Pfisterer, J., Bacon, M., ,, -OVAR, A. G. O., ,, -GCC, E. O. R. T. C., ,, ,, ,, ,, ,, -CTG, N. C. I. C., -US, N. C. I., ,, ,, and , The Gynecologic Cancer Intergroup (GCIG): History and current status, Ann Oncol, vol. 16 Suppl 8, pp. viii39-viii42, 2005.

Pages